For P2, increased TMB and more chemotherapy drug–related gene mutations were detected in the progressive tumor (Figure 3C), including TP53, CXCL12, MUC16, SHKBP1, ABCC11, CYP2C9, and a nonsense mutation (p.Y158X) of CYP26B1, than those of the primary tumor, such as SLCO1B1. This evidence concerns the gene MUC16 and neoplasm.